Healthcare Industry News: Regeneration Technologies
News Release - July 12, 2007
Regeneration Technologies Announces Launch of BioCleanse(R) MeniscusALACHUA, Fla.--(HSMN NewsFeed)--Regeneration Technologies, Inc. (RTI) (Nasdaq:RTIX ), the Florida-based processor of orthopedic and other biologic implants, announces the launch of its BioCleanseŽ meniscus at the American Orthopaedic Society for Sports Medicine (AOSSM) annual meeting in Calgary, Alberta, Canada this week.
The BioCleanse meniscus sets a new standard as the first wholly sterilized meniscus allograft on the market, meaning both the bone block and meniscal tissue are sterilized. A large animal study, conducted at Rush University under the supervision of Brian Cole, MD, revealed that the biomechanical and biochemical characteristics of the BioCleanse-sterilized meniscus are virtually identical to aseptically-processed menisci.
Thomas Wright, MD, professor of orthopaedics at the University of Florida, recently implanted a BioCleanse meniscus in a glenoid resurfacing procedure.
"Using non-sterile tissue exposes surgeons and patients to a risk of infection, which could lead to multiple further surgeries to eradicate the infection. Patient outcome is invariably negatively impacted," said Dr. Wright. "With the BioCleanse technology, we, as surgeons, can be assured that our patients receive the benefits of sterility. I would be apprehensive to use anything else."
"The launch of the BioCleanse meniscus shows RTI's continued effort in leading the evolution of biologic implants," said Brian K. Hutchison, RTI's chairman, president and chief executive officer. "For the first time in orthobiologics, surgeons have the option of using a fully sterilized meniscus."
This product launch illustrates RTI's commitment to innovation. RTI continues to develop unique technologies such as the recently launched Adjustable Length Bone-Tendon-Bone (BTB), part of RTI's precision assembled technology designed to provide consistent, precise fit to individual patients.
The BioCleanse meniscus will be available through RTI's direct representatives and distributors. Information and demonstrations will be available at the AOSSM meeting, booth #220. For further information, contact an RTI representative at (800) 624-7238.
About Regeneration Technologies, Inc.
RTI processes allograft and xenograft tissue into shaped implants for use in orthopedic and other surgeries with a commitment to science, safety and innovation.
RTI also holds the patents on BioCleanse, the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than half a million allograft implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks.
Except for historical information, any statements made in this press release about the company's anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to the company's agreements with its distributors are forward-looking statements subject to risks and uncertainties, such as those described in the company's public filings on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at www.rtix.com or the SEC's Web site at www.sec.gov.
Source: Regeneration Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.